JPRN-UMIN000010018
Completed
未知
Antiemetic effectiveness and safety of aprepitant in patients with lung cancer receiving combination therapy with carboplatin. - Antiemetic effectiveness of aprepitant in patients recieving combination therapy with carboplatin
Hamamatsu University School of Medicine0 sites134 target enrollmentStarted: February 13, 2013Last updated:
Conditionslung cancer
Overview
- Phase
- 未知
- Status
- Completed
- Enrollment
- 134
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with severe complications. Patients with nausea and vomitting in the 24 hours before chemotherapy. Patients received antiemetic therapy in the 48 hours before chemotherapy. Patients with a risk of vomitting for other reasons. (active peptic ulcer and gastrointestinal obstruction, etc)
Investigators
Similar Trials
Completed
Phase 2
The efficacy and safety of antiemetic therapy for carboplatin-containing chemotherapy-induced nausea and vomiting in patients with lung cancer.advanced lung cancerJPRN-UMIN000026739Second Division, Department of Internal Medicine, Hamamatsu university school of medicine30
Completed
Phase 2
Evaluation of anti-emetic efficacy of Aprepitant in patients undergo hematopoitic stem cell transplantation in a teaching hospitalCondition 1: Autologous bone marrow transplantation. Condition 2: emesis.Other transplanted organ and tissue statusHaematemesisIRCT201107026930N1Vice chancellor for research, Shahid Beheshti University of Medical Sciences80
Recruiting
Phase 3
Evaluation of the efficacy of Aprepitant in vomiting of children with cancerMalignant cancer.Agranulocytosis secondary to cancer chemotherapyD70.1IRCT20200204046377N1Shahid Beheshti University of Medical Sciences30
Completed
Not Applicable
Assesmentt of the efficacy of antiemetics for post procedure sedation vomiting (PPSV) in ED pediatric patientsSymptoms, signs and abnormal clinical and laboratory findings, NECKCT0000370Ajou University270
Active, not recruiting
Phase 1
Efficacy and safety of aprepitant for vaso-occlusive crisis in sickle cell childvaso-occlusive crisis for patients with sickle cell diseaseMedDRA version: 20.0Level: LLTClassification code 10040644Term: Sickle cell diseaseSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2019-000839-21-FRCentre Hospitalier Intercommunal de Créteil60